{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349127","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2026-08-13T20:03:18+00:00","discovered_at":"2026-08-13T20:04:00.065226+00:00","generated_at":"2026-08-13T20:04:11.502841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARS Pharma Q2 2026: neffy revenue $26.2M, net loss $62.3M, cuts 2H expenses","bullets":["Q2 neffy net product revenue $26.2M; total revenue $33.7M incl. $7.4M supply revenue.","Net loss $62.3M ($0.63/share); cash $143.8M at June 30, 2026.","2H 2026 SG&A+R&D guided $114-126M (cash-based $100-110M); >40% cut in cash SG&A vs 1H.","Meg Smith appointed CCO effective Aug 17, 2026; field sales expansion complete.","Phase 2b CSU trial interim data expected Q1 2027; no approved on-demand CSU flare treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349127","json":"https://secwatch.observer/filing/0001193125-26-349127.json","markdown":"https://secwatch.observer/filing/0001193125-26-349127.md","text":"https://secwatch.observer/filing/0001193125-26-349127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/0001193125-26-349127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:04:11.502841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}